Twist Bioscience (NASDAQ:TWST) Given New $33.00 Price Target at JPMorgan Chase & Co.

Twist Bioscience (NASDAQ:TWST) had its price target reduced by JPMorgan Chase & Co. from $40.00 to $33.00 in a research report sent to investors on Tuesday,Benzinga reports. JPMorgan Chase & Co. currently has an underweight rating on the stock.

A number of other equities research analysts have also issued reports on TWST. Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Guggenheim set a $50.00 price target on Twist Bioscience in a report on Friday, March 28th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.40.

Twist Bioscience Stock Down 0.3 %

Shares of NASDAQ:TWST opened at $32.67 on Tuesday. The stock has a market capitalization of $1.96 billion, a P/E ratio of -9.66 and a beta of 2.54. The stock’s 50-day moving average price is $38.81 and its 200-day moving average price is $43.74. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 12-month low of $31.56 and a 12-month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million during the quarter, compared to analysts’ expectations of $92.00 million. On average, equities analysts anticipate that Twist Bioscience will post -2.12 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 5,042 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $189,831.30. Following the sale, the chief executive officer now directly owns 655,432 shares of the company’s stock, valued at $24,677,014.80. The trade was a 0.76 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Dennis Cho sold 689 shares of the business’s stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $25,940.85. Following the completion of the sale, the insider now directly owns 110,849 shares in the company, valued at $4,173,464.85. This trade represents a 0.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,991 shares of company stock valued at $742,654 over the last quarter. Corporate insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC increased its position in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the 3rd quarter valued at $34,000. Franklin Resources Inc. increased its holdings in shares of Twist Bioscience by 3.4% in the 3rd quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after purchasing an additional 8,308 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after purchasing an additional 82,953 shares during the last quarter. Finally, Avanza Fonder AB bought a new position in shares of Twist Bioscience during the fourth quarter valued at $1,059,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.